Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics

14 de outubro de 2014 atualizado por: Astellas Pharma Europe Ltd.

An Exploratory Study to Evaluate Bladder Contractions in the Storage Phase (Non Voiding Activities) and Related Bladder Sensation in Healthy Females and Untreated Females With Overactive Bladder ("OAB") Using High Resolution and Conventional Urodynamics

This study aims to identify differences in bladder contractions during the storage phase (non voiding activities) between OAB subjects and healthy subjects, using high resolution urodynamics.

The study is divided into two parts:

  • PART 1: Consists of 5 females with overactive bladder
  • PART 2: Consists of 25 females with overactive bladder and 15 healthy females

Part 1 subjects will be enrolled followed by part 2 subjects. The data from part 1 subjects will be reviewed and analysed by a group of experts before starting the second part (part 2) of the study.

Visão geral do estudo

Descrição detalhada

The subjects will complete a total of 2 visits and a follow up telephone call (or visit at the investigator's discretion).

Upon meeting eligibility criteria subjects will be screened and complete visit at hospital (Visit 1). They will then be asked to complete procedures such micturition diary, questionnaires and if applicable discontinued their ongoing OAB medication. Upon confirmation of eligibility criteria subjects will then be enrolled and complete visit 2 within 6 to 31 days post V1. At Visit 2 subjects will complete high resolution urodynamic assessment followed by the conventional urodynamic assessment. The visit will take approximately half a day. Safety follow up phone call (or visit at investigator's discretion) will take place 4 to 6 days post visit 2.

Tipo de estudo

Intervencional

Inscrição (Real)

6

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Maastricht, Holanda, 6202
        • Maastricht University Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

35 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

OAB Subjects

  • Has history of signs and symptoms of OAB including urinary frequency, urgency or urge incontinence for greater than or equal to 3 months
  • At enrolment visit (V2) the subjects must have:

    • At least 1 episode of urgency with or without incontinence in the last 3-day micturition diary
    • Frequency of micturition greater than or equal to 8 per 24 hours period during the 3-day micturition diary period
  • At the screening visit, the subject should be either naïve to OAB treatment (e.g no prior history of medications to treat lower urinary tract symptoms (LUTS), including OAB) or currently on treatment for LUTS (including OAB) and is willing to undergo a washout period for 3 weeks

Main Exclusion criteria:

Healthy subjects

  • History of lower urinary tract symptoms (LUTS), including OAB
  • History of stress urinary incontinence, urethral sphincter incompetence and neurogenic detrusor overactivity
  • History of signs or symptoms suggestive of urinary tract infection (confirmed by positive urine analysis)
  • History of bladder outlet obstruction (not including detrusor-overactivity) for example bladder/vesicouterine pro-lapse (> grade II) or chronic obstruction
  • History of urinary tract surgery less than or equal to 6 months prior to screening
  • Has an indwelling catheter or permanent catheter fitted
  • History of pelvic area radiotherapy treatment
  • Uncontrolled diabetes mellitus
  • History of fibromyalgia
  • Pregnant or intends to become pregnant during the study or sexually active, of childbearing potential and is unwilling to utilize a reliable method of birth control (note: reliable methods are contraceptive pills of combination type, hormonal implants, injectable contraceptives, sexual abstinence or vasectomized partner)
  • Pregnancy within 6 months before screening or breast feeding within 3 months before screening
  • History of a positive hepatitis A, B surface antigen, hepatitis C antibody or HIV test result.
  • Any use of drugs of abuse within 3 months prior to screening visit.
  • History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to screening visit
  • History of drinking more than 14 units of alcohol per week (1 unit = 10 g pure alcohol = 250 ml of beer (5%) or 35 ml of spirits (35%) or 100 ml of wine (12%) within 3 months prior to screening visit
  • Is currently receiving or has a history of treatment with alpha blockers, beta receptor blockers or agonists, botulinum toxin (less than 12 months), resiniferatoxin or pelvic floor muscle relaxants less than or equal to 9 months prior to screening

Main exclusion criteria OAB subjects

  • Refer to healthy subjects exclusion criteria number 2 to 16

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Identify objective parameters to characterize Non Voiding Activity (NVA) in healthy and OAB subjects using high resolution urodynamic assessment
Prazo: During the High resolution urodynamics (Day 1)
NVA is defined as changes of pressure in the bladder lumen. These changes are measured as detrusor pressure (Pdet) calculated from substraction of intra-abdominal pressure (Pabd) from intra-vesical pressure (Pves). All Pdet with an amplitude of at least 1cm of water, frequency below 0.2 Hz and pulse duration between 5 and 60 seconds qualify as NVA.
During the High resolution urodynamics (Day 1)

Medidas de resultados secundários

Medida de resultado
Prazo
Identify NVA in healthy and OAB subjects using conventional urodynamic assessment
Prazo: During High resolution and conventional urodynamic (Day 1) assessments
During High resolution and conventional urodynamic (Day 1) assessments
Assess the subjects bladder sensations measured by visual analogue scale (VAS) and 5-points categorical scale (Appendix 8 & 7) during the high resolution urodynamic and conventional assessments
Prazo: During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)
Assess the correlation between NVA and subjects bladder sensations
Prazo: During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)
Explore NVA in a subgroup of subjects defined by the severity of OAB symptoms collected as background information (3-days bladder diary)
Prazo: During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)
Illustrate the amount of NVA detected with high resolution urodynamic test methodology compared to NVA detected with conventional urodynamic assessments
Prazo: During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)
Assess symptoms severity, bother and its impact on quality of life using: OAB-Q short form and Urogenital Distress Inventory (UDI-6) questionnaires and a 3-Day micturition bladder diary as background information to characterize the study population
Prazo: During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Cadeira de estudo: Clinical Study Manager, Astellas Pharma Europe Ltd.
  • Investigador principal: Principal Investigator, Maastricht University Medical Center, Maastricht

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de março de 2012

Conclusão Primária (Real)

1 de junho de 2012

Conclusão do estudo (Real)

1 de junho de 2012

Datas de inscrição no estudo

Enviado pela primeira vez

13 de fevereiro de 2012

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de fevereiro de 2012

Primeira postagem (Estimativa)

29 de fevereiro de 2012

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

15 de outubro de 2014

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de outubro de 2014

Última verificação

1 de outubro de 2014

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 905-EC-010

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

3
Se inscrever